Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: VAXINE PTY LTD
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2018-09-20 to 2023-08-14
Current total value of award: $5832656
Description: TO ADVANCE THE NOVEL H7-ADVAX PANDEMIC VACCINE CANDIDATES THROUGH TO PHASE 1 CLINICAL TRIALS THROUGH DELIVERY TO THE GOVERNMENT OF: PRELIMINARY DATA REGARDING ADJUVANT FOR FORMULATIONS (BASE REQUIREMENT/CLIN 001); MANUFACTURED PRODUCT (RELEASE) FOR S